Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.

[1]  M. Botteman,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A cost-effectiveness analysis , 2013, Journal of medical economics.

[2]  M. Caraglia,et al.  Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure? , 2013, Expert opinion on biological therapy.

[3]  Petko Ivanov,et al.  A single-dose study of denosumab in patients with various degrees of renal impairment , 2012 .

[4]  F. Saad,et al.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  F. Saad,et al.  Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial , 2012, The Lancet.

[6]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[7]  J. Wark,et al.  Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg , 2012, Osteoporosis International.

[8]  M L Kilgore,et al.  Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006 , 2011, Prostate Cancer and Prostatic Diseases.

[9]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[10]  Thomas E. Moritz,et al.  The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis. , 2010, Urology.

[11]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[12]  B. Clarke.  Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer , 2010 .

[13]  K. Kitikidou,et al.  Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Thomas E. Moritz,et al.  Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. , 2009, The Journal of urology.

[15]  L. Assael,et al.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. , 2009, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[16]  X. Mariette,et al.  Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Parnes,et al.  Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents , 2009, Cancer investigation.

[18]  B. Clarke,et al.  Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates , 2009 .

[19]  L. Bosserman,et al.  Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. , 2009, The Journal of urology.

[20]  C. Brunelli,et al.  Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  M. Dimopoulos,et al.  Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  J. Thüroff,et al.  Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. , 2008, European urology.

[23]  T. Dodson,et al.  Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. , 2008, Journal of oral and maxillofacial surgery.

[24]  D. Lorich,et al.  Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. , 2008, The New England journal of medicine.

[25]  C. V. Van Poznak,et al.  Significance and impact of bisphosphonate-induced acute phase responses , 2007, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[26]  F. Jadu,et al.  A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  P. Rodrigues,et al.  Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open‐label controlled study , 2007, International journal of urology : official journal of the Japanese Urological Association.

[28]  P. Kantoff,et al.  Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Goss,et al.  Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. , 2007, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[30]  J. Gottesman,et al.  The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. , 2007, Clinical genitourinary cancer.

[31]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. , 2007, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[33]  C. Ryan,et al.  Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. , 2006, The Journal of urology.

[34]  E. Terpos,et al.  Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single‐centre experience in 303 patients , 2006, British journal of haematology.

[35]  K. Anstrom,et al.  Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  C. Scully,et al.  Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. , 2006, Oral oncology.

[37]  M. Dimopoulos,et al.  Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  T. Polascik,et al.  Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. , 2005, Urology.

[39]  R. Marx,et al.  Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. , 2005, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[40]  F. Saad,et al.  Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. M. López,et al.  Fracture risk in patients with prostate cancer on androgen deprivation therapy , 2005, Osteoporosis International.

[42]  E. Small,et al.  Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Beitz,et al.  Renal failure with the use of zoledronic acid. , 2003, The New England journal of medicine.

[44]  M. Parmar,et al.  A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). , 2003, Journal of the National Cancer Institute.

[45]  R. Marx.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[46]  J. Eastham,et al.  Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. , 2003, The Journal of urology.

[47]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[48]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[49]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 1995. , 2002, European journal of cancer.

[50]  M. Rogers,et al.  Overview of bisphosphonates , 1997, Cancer.

[51]  S. Jacobs.  Spread of prostatic cancer to bone. , 1983, Urology.